Screening / early detection · curated MDI catalog

Cancer screening and early-detection molecular tests

These tests are used before a cancer diagnosis to look for an early molecular signal in a defined screening or surveillance setting. A screening result is not by itself a diagnosis.

30 curated profiles currently match this page. MDI lists them alphabetically and does not rank tests by isolated performance numbers, evidence counts, price or popularity.

  • Avantect Ovarian Cancer Test — Cell-free DNA blood LDT intended as an aid to earlier ovarian-cancer detection in women at elevated risk.
  • Avantect Pancreatic Cancer Test — Blood-based multi-analyte, multiomic test intended to support earlier pancreatic cancer detection in elevated-risk patients.
  • CancerFind — Blood-based multi-cancer early detection assay using methylation, copy-number and fragmentomic features.
  • Cancerguard — Multi-cancer early detection laboratory-developed test for adults 50–84; breast/prostate screening and precancer detection are outside the documented current use.
  • CanScan — Blood-based multi-cancer early detection test using low-depth WGS and AI integration of fragmentomic, genomic and inferred epigenomic cfDNA features.
  • Caris Detect — Blood-based multi-cancer early detection LDT using whole-genome and whole-transcriptome sequencing with AI.
  • Cologuard — Stool-based colorectal cancer screening test for average-risk adults.
  • Cologuard Plus — Prescription multitarget stool-based colorectal cancer screening test for average-risk adults age 45 years or older.
  • ColoHealth — Blood-based methylated SEPT9 colorectal cancer testing family; current ColoHealth Direct LDT and historical FDA device lineage are modeled separately.
  • ColoScape — Multiplex plasma cfDNA mutation-and-methylation assay used in colorectal cancer screening-triage and diagnostic-aid contexts.
  • ColoSense — FDA-approved qualitative stool RNA and occult-hemoglobin colorectal cancer screening test for average-risk adults age 45 years or older.
  • COLOTECT CRC Screening — Stool-based colorectal cancer screening test combining DNA methylation and fecal occult blood detection in the current 3.0 configuration.
  • EPISEEK — Blood-based multi-cancer early detection LDT analyzing abnormal DNA methylation signals associated with more than 60 cancer types.
  • FirstLook Lung — Blood-based cfDNA fragmentomics laboratory-developed test used as an adjunct in the lung-cancer screening pathway; not a replacement for LDCT.
  • Galleri — Prescription-only multi-cancer early detection test.
  • GASTROClear — Blood-based miRNA test for early detection of gastric cancer.
  • LucenceINSIGHT — Prescription blood-based multi-cancer early detection family using ctDNA and viral DNA with machine-learning tissue localization.
  • LUNGClear — Blood-based miRNA test for early detection of lung cancer.
  • Oncoguard Liver — Blood-based aid for HCC detection in an at-risk surveillance population.
  • OneTest for Cancer — Blood-based multi-cancer early detection LDT combining multiple serum tumor biomarkers with a machine-learning risk algorithm.
  • OverC Multi-Cancer Detection — Blood-based cfDNA methylation multi-cancer early detection test with six-cancer current product scope; jurisdiction-specific regulatory status.
  • PanTum Detect — Whole-blood multi-cancer screening aid detecting Apo10/DNaseX and TKTL1 signals in monocytes using EDIM/flow-cytometry-based methodology.
  • ProVue Lung — Proteomics-based blood LDT designed to complement LDCT lung-cancer screening in high-risk adults.
  • Shield — Blood-based colorectal cancer screening test.
  • SimpleScreen CRC — FDA-approved blood-based colorectal cancer screening test for average-risk adults age 45 and older.
  • SimpleScreen Lung — Blood-based multiomic LDT intended to increase lung-cancer screening participation among eligible high-risk adults not completing LDCT.
  • SPOT-MAS 10 — Blood-based multi-cancer screening test using cfDNA methylation and fragmentomic signals with machine learning.
  • SPOT-MAS CRC — Plasma SEPTIN9 DNA methylation test for colorectal cancer early detection.
  • SPOT-MAS Lung — Plasma multi-omic cfDNA test for early detection of lung cancer.
  • Trucheck Intelli — Blood-based multi-cancer early detection test that detects circulating tumor cells and reports likely tissue/tumor context across many solid tumors.

How to interpret these records

Clinical purpose comes first. Historical evidence remains attached to the assay version that was actually studied. Evidence counts describe curation coverage, not test quality. Commercial availability is separate from authorization, reimbursement, eligibility and appropriate use.

Find all tests · Understand the evidence · Methodology & provenance